Federal Register / Vol. 86, No. 9 / Thursday, January 14, 2021 / Notices 3165 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; BRAIN Review (U01 and 

R01). 

Date: February 12, 2021. 

Time: 8:00 a.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Mir Ahamed Hossain, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, NINDS/NIH/DHHS, 

Neuroscience Center, 6001 Executive Blvd., 

Suite 3208, MSC 9529, Rockville, MD 20852, 

(301) 496–9223, mirahamed.hossain@

nih.gov. 

Name of Committee: Neurological Sciences 

Training Initial Review Group; NST–2 

Subcommittee NINDS Post-Doc Fellowship 

Review. 

Date: February 17–19, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Deanna Lynn Adkins, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Neuroscience Center, 

Rockville, MD 20852, 301–496–9223, 

deanna.adkins@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders B. 

Date: February 25, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Joel A. Saydoff, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH NSC, 6001 Executive Blvd., 

Room 3205, MSC 9529, Rockville, MD 20852, 

(301) 496–9223, joel.saydoff@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Exploratory Udall Centers 

P20 Review. 

Date: February 25, 2021. 

Time: 10:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Marilyn Moore-Hoon, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, National Institute of Neurological 

Disorders and Stroke, Rockville, MD 20852, 

301 827–9087, mooremar@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Advancing Careers of 

Diverse Research. 

Date: February 25–26, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Deanna Lynn Adkins, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Neuroscience Center, 

Rockville, MD 20852, 301–496–9223, 

deanna.adkins@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Udall Centers P50 Review. 

Date: March 1–2, 2021. 

Time: 10:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Marilyn Moore-Hoon, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, National Institute of Neurological 

Disorders and Stroke, Rockville, MD 20852, 

301 827–9087, mooremar@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: January 8, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00650 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Nonhuman Primate Reagent 

Resource (U24 Clinical Trial Not Allowed). 

Date: February 8, 2021. 

Time: 2:30 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G41, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Tara Capece, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G41, Rockville, MD 

20852, 240–191–4281, capecet2@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 8, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00649 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


khammond on DSKJM1Z7X2PROD with NOTICES
3166 Federal Register / Vol. 86, No. 9 / Thursday, January 14, 2021 / Notices 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; PrEP for 

HIV Prevention among Substance Using 

Populations (R01—Clinical Trial Optional). 

Date: February 11, 2021. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Trinh T. Tran, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–5843, trinh.tran@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; BRAIN 

Initiative: Tools for Germline Gene Editing in 

Marmosets (U01—Clinical Trial Not 

Allowed). 

Date: February 17, 2021. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 827–5819, gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Exploiting Genome or Epigenome Editing to 

Functionally Validate Genes or Variants 

Involved in Substance Use Disorders (R21/ 

R33 Clinical Trial Not Allowed). 

Date: February 18, 2021. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ipolia R. Ramadan, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–4471, ramadanir@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Centers Review. 

Date: February 26—March 1, 2021. 

Time: 10:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ipolia R Ramadan, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC, 6021 Bethesda, MD 20892, 

(301) 827–4471, ramadanir@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: January 8, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00574 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Citizenship and Immigration 

Services 

[OMB Control Number 1615–0124] 

Agency Information Collection 

Activities; Extension, Without Change, 

of a Currently Approved Collection: 

Consideration of Deferred Action for 

Childhood Arrivals 

AGENCY: U.S. Citizenship and 

Immigration Services, Department of 

Homeland Security. 

ACTION: 30-Day notice. 

SUMMARY: The Department of Homeland 

Security (DHS), U.S. Citizenship and 

Immigration Services (USCIS) will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and clearance in accordance 

with the Paperwork Reduction Act of 

1995. The purpose of this notice is to 

allow an additional 30 days for public 

comments. 

DATES: Comments are encouraged and 

will be accepted until February 16, 

2021. 

ADDRESSES: Written comments and/or 

suggestions regarding the item(s) 

contained in this notice, especially 

regarding the estimated public burden 

and associated response time, must be 

submitted via the Federal eRulemaking 

Portal website at http://

www.regulations.gov under e-Docket ID 

number USCIS–2012–0012. All 

submissions received must include the 

OMB Control Number 1615–0124 in the 

body of the letter, the agency name and 

Docket ID USCIS–2012–0012. 

FOR FURTHER INFORMATION CONTACT: 

USCIS, Office of Policy and Strategy, 

Regulatory Coordination Division, 

Samantha Deshommes, Chief, 

Telephone number (240) 721–3000 

(This is not a toll-free number; 

comments are not accepted via 

telephone message.). Please note contact 

information provided here is solely for 

questions regarding this notice. It is not 

for individual case status inquiries. 

Applicants seeking information about 

the status of their individual cases can 

check Case Status Online, available at 

the USCIS website at http://

www.uscis.gov, or call the USCIS 

Contact Center at (800) 375–5283; TTY 

(800) 767–1833. 

SUPPLEMENTARY INFORMATION: 

Comments 

The original information collection 

notice for an extension without change 

was previously published in the Federal 

Register on July 20, 2020, at 85 FR 

43866, allowing for a 60-day public 

comment period. USCIS did receive 26 

comments in connection with the 60- 

day notice. USCIS subsequently 

published a second notice in the 

Federal Register on November 13, 2020 

at 85 FR 72682 for a revision to the 

collection of information. USCIS 

published a notice of withdrawal in the 

Federal Register for the revision action 

on December 31, 2020 at 85 FR 86946, 

which incorrectly listed the original 

notice publication as 85 FR 46882. 

You may access the information 

collection instrument with instructions, 

or additional information by visiting the 

Federal eRulemaking Portal site at: 

http://www.regulations.gov and enter 

USCIS–2012–0012 in the search box. 

The comments submitted to USCIS via 

this method are visible to the Office of 

Management and Budget and comply 

with the requirements of 5 CFR 

1320.12(c). All submissions will be 

posted, without change, to the Federal 

eRulemaking Portal at http://

www.regulations.gov, and will include 

any personal information you provide. 

Therefore, submitting this information 

makes it public. You may wish to 

consider limiting the amount of 

personal information that you provide 

in any voluntary submission you make 

to DHS. DHS may withhold information 

provided in comments from public 

viewing that it determines may impact 

the privacy of an individual or is 

offensive. For additional information, 

please read the Privacy Act notice that 

is available via the link in the footer of 

http://www.regulations.gov. 

Written comments and suggestions 

from the public and affected agencies 

should address one or more of the 

following four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 


khammond on DSKJM1Z7X2PROD with NOTICES